Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first‐in‐human study and during experimental human endotoxaemia in healthy subjects

AIMS: Adrenomedullin (ADM) is an important regulator of endothelial barrier function and vascular tone, and may represent a novel treatment target in sepsis. The non‐neutralizing ADM antibody adrecizumab has shown promising results in preclinical sepsis models. In the present study, we investigated...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Clin Pharmacol
Hlavní autoři: Geven, Christopher, van Lier, Dirk, Blet, Alice, Peelen, Roel, ten Elzen, Bas, Mebazaa, Alexandre, Kox, Matthijs, Pickkers, Peter
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089825/
https://ncbi.nlm.nih.gov/pubmed/29856470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13655
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky